Based on the Aarti Drugs Limited stock forecast from 1 analysts, the average analyst target price for Aarti Drugs Limited is INR 470.00 over the next 12 months. Aarti Drugs Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aarti Drugs Limited is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Aarti Drugs Limited’s stock price was INR 414.35. Aarti Drugs Limited’s stock price has changed by +6.24% over the past week, -8.63% over the past month and -18.65% over the last year.
No recent analyst target price found for Aarti Drugs Limited
No recent average analyst rating found for Aarti Drugs Limited
Company Overview Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India. Read Less
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclod...Read More
Frequently Asked Questions About Aarti Drugs Limited (AARTIDRUGS:NSE) Stock
Based on ratings from 1 analysts Aarti Drugs Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
AARTIDRUGS:NSE stock's dividend yield is 0.24%.
Our analysis grades AARTIDRUGS:NSE stock's dividend yield at F. This means that AARTIDRUGS:NSE stock's dividend yield is above 22% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AARTIDRUGS:NSE may be a poor dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for AARTIDRUGS:NSE is INR 470.00 over the next 12 months. The maximum analyst target price is INR 470 while the minimum anlayst target price is INR 470.
AARTIDRUGS:NSE stock's Price/Earning ratio is 24.18.
Our analysis grades AARTIDRUGS:NSE stock's Price / Earning ratio at C. This means that AARTIDRUGS:NSE stock's Price/Earning ratio is above 27% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AARTIDRUGS:NSE may be undervalued for its sector.
The last closing price of AARTIDRUGS:NSE's stock was INR 414.35.
The most recent market capitalization for AARTIDRUGS:NSE is INR 36.54B.
Based on targets from 1 analysts, the average taret price for AARTIDRUGS:NSE is projected at INR 470.00 over the next 12 months.
This means that AARTIDRUGS:NSE's stock price may go up by +13.43% over the next 12 months.
We can't find any ETFs which contains Aarti Drugs Limited's stock.
As per our most recent records Aarti Drugs Limited has 1,064 Employees.
Aarti Drugs Limited's registered address is Mahendra Industrial Estate, Mumbai, India, 400 022.
You can get more information about it from Aarti Drugs Limited's website at https://www.aartidrugs.co.in.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Aarti Drugs Limited (AARTIDRUGS:NSE) Stock
Based on ratings from 1 analysts Aarti Drugs Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
AARTIDRUGS:NSE stock's dividend yield is 0.24%.
Our analysis grades AARTIDRUGS:NSE stock's dividend yield at F. This means that AARTIDRUGS:NSE stock's dividend yield is above 22% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AARTIDRUGS:NSE may be a poor dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for AARTIDRUGS:NSE is INR 470.00 over the next 12 months. The maximum analyst target price is INR 470 while the minimum anlayst target price is INR 470.
AARTIDRUGS:NSE stock's Price/Earning ratio is 24.18.
Our analysis grades AARTIDRUGS:NSE stock's Price / Earning ratio at C. This means that AARTIDRUGS:NSE stock's Price/Earning ratio is above 27% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AARTIDRUGS:NSE may be undervalued for its sector.
The last closing price of AARTIDRUGS:NSE's stock was INR 414.35.
The most recent market capitalization for AARTIDRUGS:NSE is INR 36.54B.
Based on targets from 1 analysts, the average taret price for AARTIDRUGS:NSE is projected at INR 470.00 over the next 12 months.
This means that AARTIDRUGS:NSE's stock price may go up by +13.43% over the next 12 months.
We can't find any ETFs which contains Aarti Drugs Limited's stock.
As per our most recent records Aarti Drugs Limited has 1,064 Employees.
Aarti Drugs Limited's registered address is Mahendra Industrial Estate, Mumbai, India, 400 022.
You can get more information about it from Aarti Drugs Limited's website at https://www.aartidrugs.co.in.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AARTIDRUGS:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
